Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) Shares Outstanding (2022 - 2025)

Oramed Pharmaceuticals' Shares Outstanding history spans 4 years, with the latest figure at $39.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding changed N/A year-over-year to $39.3 million; the TTM value through Dec 2025 reached $39.3 million, changed N/A, while the annual FY2025 figure was $39.3 million, N/A changed from the prior year.
  • Shares Outstanding reached $39.3 million in Q4 2025 per ORMP's latest filing, down from $40.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $40.9 million in Q1 2025 to a low of $38564.0 in Q1 2022.
  • Average Shares Outstanding over 4 years is $24.6 million, with a median of $39.6 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding: soared 102891.33% in 2023, then decreased 0.18% in 2024.
  • A 4-year view of Shares Outstanding shows it stood at $39.6 million in 2022, then grew by 1.96% to $40.3 million in 2023, then dropped by 0.32% to $40.2 million in 2024, then fell by 2.33% to $39.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Shares Outstanding are $39.3 million (Q4 2025), $40.8 million (Q3 2025), and $40.8 million (Q2 2025).